Anna Novotney-Barry

Vice President
Clinical Development

Anna Novotney-Barry joined Aviragen Therapeutics as Vice President of Clinical Development in November 2013.

Mrs. Novotney-Barry served as Vice President Clinical Development at Inhibitex, Inc. from March 2010 until August 2012, where compounds in clinical development included both small molecule anti-virals to treat Hepatitis C and Herpes Zoster as well as a monoclonal antibody directed at bacterial infection. Prior to Inhibitex, she held several global scientific and management positions within Clinical Development at UCB Pharma SA, including responsibility for leading clinical program development for certain monoclonal antibodies within the immunology therapeutic area. Earlier in her career which spans more than 25 years, she held a number of positions within Clinical Development or Drug Discovery at Solvay, Cryolife, and Searle.

Mrs. Novotney-Barry received a B.S. degree in Biology from the University of Illinois at Champaign-Urbana and M.S. degree in Immunology from Southern Illinois University at Edwardsville.

Log In

Create an account